Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Buy
- Symbol (MBII)
- Company Marrone Bio Innovations, Inc.
- Price $0.80
- Changes Percentage (-20.19%)
- Change -$0.2
- Day Low $0.75
- Day High $1.02
- Year High $1.50
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/15/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.12
- Trailing P/E Ratio -6.8213675213675
- Forward P/E Ratio -6.8213675213675
- P/E Growth -6.8213675213675
- Net Income $-16,554,000
Income Statement
Quarterly
Annual
Latest News of MBII
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Sixers, Joel Embiid agree to three-year max contract extension: 'I want to be here the rest of my career'
Philadelphia 76ers lock in Joel Embiid with a lucrative contract extension, solidifying his future with the team. The NBA star aims to bring a championship to the city he loves, highlighting his commi...
By Fox News | 1 week ago -
Joel Embiid, 76ers agree to max extension worth $301 million: Sources
Joel Embiid and the Philadelphia 76ers reached a max extension deal worth $301 million over five years, making it one of the top three richest contracts in NBA history. Embiid expressed his commitment...
By The New York Times | 1 week ago -
Joel Embiid signing $193 million extension in statement 76ers move
Joel Embiid is set to sign a $193 million extension with the Philadelphia 76ers, putting an end to rumors of him leaving. The team looks to strengthen with star players like Paul George and Tyrese Max...
By New York Post | 1 week ago
